FDA launches EAST initiative to expand drug quality sampling and testing

18 November 2026 — The U.S. Food and Drug Administration (FDA) has launched its Enhanced Approach for Sampling and Testing (EAST), an initiative designed to expand post-market surveillance of drug quality across domestic and international manufacturing supply chains.

The programme combines modern screening techniques with traditional testing methods to evaluate a broader range of drug products, identify potential quality issues earlier and generate data to support the agency’s risk-based regulatory oversight.

Expanding quality surveillance across global supply chains

The U.S. drug supply depends on extensive networks of domestic and international manufacturers. Monitoring product quality across these geographically distributed supply chains presents significant challenges for regulatory oversight.

According to the FDA, EAST is designed to increase the volume, variety and geographical coverage of drug products evaluated while working within existing resource constraints. The approach aims to provide a more representative picture of drug quality across the U.S. supply chain without compromising the analytical rigour and evidentiary standards required for regulatory decision-making.

The initiative expands direct quality evaluations across a broader range of manufacturers and therapeutic classes, including products manufactured both in the United States and abroad.

“The EAST initiative gives us an enhanced way to monitor drug quality across an increasingly complex global supply chain,” said Dr Michael Kopcha, PhD, RPh, Director of the FDA’s Office of Pharmaceutical Quality. “With this approach, we can gather more information about drug quality and make decisions to help protect public health.”

Commercial sampling and key quality attributes

Under EAST, the FDA purchases drug samples commercially from retail pharmacies and wholesale distributors. This allows the agency to evaluate products available to patients and consumers through commercial distribution channels.

Product selection is intended to ensure broad representation across manufacturers, therapeutic classes and geographical regions.

The primary quality evaluations focus on three critical attributes:

  • Identity: confirming that the product contains the correct active pharmaceutical ingredient (API).
  • Purity: evaluating the product for potential impurities.
  • Potency: verifying the amount of the active pharmaceutical ingredient in the product.

Additional testing may be conducted when specific concerns arise regarding other product quality attributes.

Confirmatory testing and publication of results

Samples referred for further evaluation will undergo additional confirmatory testing using established and validated analytical methods, including methods described in the United States Pharmacopeia (USP).

The FDA will report EAST testing results in the “Results” section of its Drug Quality Sampling and Testing Programs webpage.

The agency will use the resulting data to identify potential quality risks, support risk-based assessments and inform regulatory policy. The findings will also contribute to decisions on whether regulatory action is warranted and help guide future inspection planning.

Implications for GMP inspections

EAST also has implications for pharmaceutical manufacturing oversight and GMP inspection planning.

Commercial sampling and laboratory testing provide an additional source of information about the quality of medicinal products available on the U.S. market. Although EAST focuses on commercial sampling and laboratory testing rather than GMP inspections, its findings can contribute to the broader regulatory assessment of drug quality.

When considered in the context of manufacturing oversight, market-based testing results may help identify potential areas of concern that warrant closer regulatory attention. The FDA explicitly identifies risk-based assessment and future inspection planning among the intended uses of data generated through EAST.

For pharmaceutical manufacturers, this reinforces the importance of maintaining an effective Pharmaceutical Quality System (PQS) and ensuring consistent product quality. Market surveillance provides an additional perspective on the quality of products reaching patients, complementing the information obtained through manufacturing oversight.

Strengthening risk-based regulatory oversight

By combining broader commercial sampling with modern screening techniques and established confirmatory methods, EAST expands the FDA’s ability to assess the quality of medicines supplied to the U.S. market.

The initiative also strengthens the connection between post-market quality surveillance and regulatory oversight, allowing laboratory testing results to contribute to risk assessment, regulatory decisions and the planning of future inspections.

POPULAR